CN117120035A - 用于眼部使用的拉喹莫德制剂 - Google Patents

用于眼部使用的拉喹莫德制剂 Download PDF

Info

Publication number
CN117120035A
CN117120035A CN202280022389.2A CN202280022389A CN117120035A CN 117120035 A CN117120035 A CN 117120035A CN 202280022389 A CN202280022389 A CN 202280022389A CN 117120035 A CN117120035 A CN 117120035A
Authority
CN
China
Prior art keywords
formulation
pharmaceutically acceptable
laquinimod
agent
ocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280022389.2A
Other languages
English (en)
Chinese (zh)
Inventor
H·万曼
M·特恩格伦
H·埃里克松
A·布尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Publication of CN117120035A publication Critical patent/CN117120035A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280022389.2A 2021-04-01 2022-03-31 用于眼部使用的拉喹莫德制剂 Pending CN117120035A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21166691.2 2021-04-01
EP21166691 2021-04-01
PCT/EP2022/058523 WO2022207773A1 (en) 2021-04-01 2022-03-31 Laquinimod formulation for ocular use

Publications (1)

Publication Number Publication Date
CN117120035A true CN117120035A (zh) 2023-11-24

Family

ID=75362492

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280022389.2A Pending CN117120035A (zh) 2021-04-01 2022-03-31 用于眼部使用的拉喹莫德制剂

Country Status (14)

Country Link
US (1) US20240180819A1 (enExample)
EP (2) EP4461364B1 (enExample)
JP (1) JP2024516929A (enExample)
KR (1) KR20230165260A (enExample)
CN (1) CN117120035A (enExample)
AU (1) AU2022248724A1 (enExample)
BR (1) BR112023018932A2 (enExample)
CA (1) CA3212851A1 (enExample)
ES (1) ES3014261T3 (enExample)
IL (1) IL305997A (enExample)
MX (1) MX2023010971A (enExample)
PL (1) PL4312986T3 (enExample)
WO (1) WO2022207773A1 (enExample)
ZA (1) ZA202309969B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119523881A (zh) * 2024-04-28 2025-02-28 中国人民解放军海军军医大学第二附属医院 一种s100a9抑制剂凝胶剂及其制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL320428A (en) 2022-11-04 2025-06-01 Qlaris Bio Inc Topical ophthalmic administration of cromolyns
CN118892446A (zh) * 2023-04-27 2024-11-05 维眸生物科技(浙江)有限公司 一种含vvn001的眼科组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
EP3068395A4 (en) * 2013-11-15 2017-07-12 Teva Pharmaceutical Industries Ltd. Treatment of glaucoma using laquinimod
US9694003B2 (en) * 2015-10-15 2017-07-04 Bridge Pharma, Inc. Formulations and methods for treating high intraocular pressure
IL289109B2 (en) * 2019-06-19 2025-10-01 Tarsus Pharmaceuticals Inc Isoxazoline formulations against parasites and methods for treating blepharitis
KR20220118419A (ko) 2019-12-19 2022-08-25 액티브 바이오테크 에이비 과도한 혈관신생과 관련된 안구 질병의 치료를 위한 화합물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119523881A (zh) * 2024-04-28 2025-02-28 中国人民解放军海军军医大学第二附属医院 一种s100a9抑制剂凝胶剂及其制备方法

Also Published As

Publication number Publication date
AU2022248724A1 (en) 2023-11-02
MX2023010971A (es) 2023-09-27
KR20230165260A (ko) 2023-12-05
JP2024516929A (ja) 2024-04-18
US20240180819A1 (en) 2024-06-06
PL4312986T3 (pl) 2025-02-17
BR112023018932A2 (pt) 2023-10-10
CA3212851A1 (en) 2022-10-06
EP4312986B1 (en) 2024-10-23
EP4461364A3 (en) 2024-11-27
ZA202309969B (en) 2025-03-26
EP4312986C0 (en) 2024-10-23
EP4461364A2 (en) 2024-11-13
EP4461364B1 (en) 2026-04-22
EP4312986A1 (en) 2024-02-07
WO2022207773A1 (en) 2022-10-06
ES3014261T3 (en) 2025-04-21
IL305997A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
JP5668476B2 (ja) カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
US8614178B2 (en) Pharmaceutical composition for treatment of dry eye syndrome
CN117120035A (zh) 用于眼部使用的拉喹莫德制剂
KR102766771B1 (ko) 국소형 시클로스포린 함유 제형 및 그의 용도
EA034839B1 (ru) Офтальмологический раствор
JP2021518352A (ja) チモロールを含む医薬組成物
JP2021515758A (ja) ネビボロールを含む医薬組成物
CN115066232A (zh) 用于治疗眼病的组合物和方法
JP2026067867A (ja) Ｄ２ｏを含む眼科用組成物
US20240165018A1 (en) Hydrogel implants for lowering intraocular pressure
WO2015188127A1 (en) Oil-free and fat-free aqueous suspensions of cyclosporin
JP2023530188A (ja) 高分子量ヒアルロン酸の眼科用薬物輸送ビヒクルとしての使用
US20220211618A1 (en) Injectable triamcinolone formulations
KR20140069210A (ko) 안과적 겔 조성물
HK40102218B (en) Laquinimod formulation for ocular use
HK40102218A (en) Laquinimod formulation for ocular use
EA051540B1 (ru) Композиция лаквинимода для глазного применения
US20240197691A1 (en) Tacrolimus compositions and methods of use
WO2025114562A1 (en) Intravitreal spironolactone suspension
EP4719350A1 (en) Stable cyclosporine ophthalmic formulation and manufacturing process thereof
WO2025133214A1 (en) Ophthalmic polypeptide compositions for the treatment of posterior eye disorders
CN121041212A (zh) 一种眼用纳米制剂及其制备和应用
CN109010270A (zh) 一种阳离子材料制备的眼用乳

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination